866-997-4948(US-Canada Toll Free)

Mirapex Analysis and Estimates from 2002 to 2020

Published By :

GlobalData

Published Date : Jul 2011

Category :

Therapeutic Area

No. of Pages : 35 Pages



GlobalDatas pharmaceuticals report, Mirapex Analysis and Estimates from 2002 to 2020 provides Mirapex sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Parkinson's Disease market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. 

Scope
  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Mirapex including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of the drug including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2011-2020 for Mirapex in each of the seven major markets
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 4
2.1 Parkinsons Disease 4
2.2 Symptoms of Parkinsons Disease 4
2.3 Diagnosis of Parkinsons Disease 5
2.4 Parkinsons Disease Treatment Strategies 5
2.5 Parkinsons Disease Market 6
2.6 Epidemiology 6
2.7 Parkinsons Disease by Age and Gender 6
2.8 Etiology 7
2.9 GlobalData Report Guidance 7

3 Parkinsons Disease: Market Characterization 8
3.1 Parkinsons Disease Market 8
3.2 Parkinsons Disease Market Forecasts and CAGR 8
3.3 Factors Affecting Parkinsons Disease Market 9
3.3.1 High Prevalence: Parkinsons Disease is the Second Most Frequent Neurodegenerative Disorder 9
3.3.2 Increase in Old Age Population 9
3.3.3 Patent Expiry of Prominent Drugs 9

4 Stages of Parkinsons Disease and Comparison of Treatments 10
4.1 The Hoehn and Yahr Scale 10
4.2 Modified Hoehn and Yahr Scale 10
4.3 The UPDRS 11

5 Staging of Parkinsons Disease 14
5.1 Distribution of Parkinsons Disease Patients by Age Groups 14
5.2 Distribution of Patients by Stages 14

6 Mirapex 15
6.1 Introduction 15
6.2 Mechanism of Action 15
6.3 Clinical Studies 15
6.3.1 Studies in Patients with Early Parkinson's Disease 15
6.3.2 Studies in Patients with Advanced Parkinson's Disease 16
6.3.3 Efficacy of Mirapex as Monotherapy in Mild to Moderate Parkinsons Disease 16
6.4 Approval History of Mirapex 17
6.5 Factors Affecting Sales of Mirapex 17
6.5.1 Used in Multiple Regimens 17
6.5.2 Better Efficacy 17
6.5.3 Launch of Mirapex ER 17
6.5.4 Patent Expiry of Mirapex 17
6.5.5 Behavioral Addictions 18
6.6 Drug Evaluation 18
6.6.1 Drug Risk Benefit Score 18
6.6.2 Intensity of Competition 19
6.7 Sales Estimates 20
6.7.1 Target Patient Pool for Mirapex 20
6.7.2 Dosing 20
6.7.3 Market Penetration 21
6.7.4 Annual Cost of Therapy 21
6.7.5 Sales Estimates of Mirapex 22

7 Parkinson Disease Market: Appendix 31
7.1 Market Definitions 31
7.2 List of Abberiviations 31
7.3 Research Methodology 31
7.3.1 Coverage 31
7.3.2 Secondary Research 31
7.3.3 Forecasting 32
7.3.4 Number of Patients Approved to take the Drug 32
7.3.5 Net Penetration of Drug 32
7.3.6 Net Annual Dosing 33
7.3.7 Annual Cost of Therapy 33
7.3.8 Primary Research 33
7.3.9 Expert Panels 34
7.4 Drug Sales Estimates Model 34
7.5 Contact Us 34
7.6 Disclaimer 34
7.7 Sources 35

List of Table


Table 1: Clinical Motor and Nonmotor Features of Parkinsons Disease 4
Table 2: Hoehn and Yahr Stages of Parkinsons Disease 10
Table 3: Hoehn and Yahr Stages of Parkinsons Disease 10
Table 4: Four Items, Part 1 of UPDRS 11
Table 5: Thirteen Items, Part 2 of UPDRS 11
Table 6: Fourteen Items, Part 3 of UPDRS 12
Table 7: Fourteen Items, Part 3 of UPDRS 12
Table 8: Distribution of Parkinsons Patients According to Hoehn and Yahr Classification 14
Table 9: Approval History of Mirapex 17
Table 10: Drug Risk Benefit Score of Mirapex 18
Table 11: Efficacy Comparison of Mirapex with Other Dopamine Agonists 19
Table 12: Efficacy Comparison of Mirapex with Other Competitors 19
Table 13: Dosing Schedule of Mirapex for Parkinsons Disease 20
Table 14: Annual Cost of Mirapex for Parkinsons Disease, 2010 21
Table 15: Mirapex, Parkinsons Disease, Global, Sales Estimates ($m), 20022020 22
Table 16: Mirapex, Parkinsons Disease, The US, Sales Estimates ($m), 20022020 23
Table 17: Mirapex, Parkinsons Disease, The UK, Sales Estimates ($m), 20022020 24
Table 18: Mirapex, Parkinsons Disease, France, Sales Estimates ($m), 20022020 25
Table 19: Mirapex, Parkinsons Disease, Germany, Sales Estimates ($m), 20022020 26
Table 20: Mirapex, Parkinsons Disease, Italy, Sales Estimates ($m), 20022020 27
Table 21: Mirapex, Parkinsons Disease, Spain, Sales Estimates ($m), 20022020 28
Table 22: Mirapex, Parkinsons Disease, Japan, Sales Estimates ($m), 20032020 29

List of Chart


Figure 1: Current Pharmacologic Therapies for Parkinsons Disease and Their Potential Sites of Action in the CNS 5
Figure 2: The Age-Specific Prevalence Rates of Parkinsons Disease in the Elderly Among Five European Countries, 2003 6
Figure 3: Parkinsons Disease, Global, Market Size Estimates ($bn), 20102020 8
Figure 4: Proportion of Population 60 Years or Older, World, 1950-2050 9
Figure 5: Points Distribution of UPDRS 13
Figure 6: Distribution of Parkinsons Disease Patients by Hoehn & Yahr Classification 14
Figure 7: Drug Model Diagram of Mirapex in the US, EU and Japan 20
Figure 8: Mirapex, Parkinsons Disease, Global, Sales Estimates ($m), 20022020 22
Figure 9: Mirapex, Parkinsons Disease, The US, Sales Estimates ($m), 20022020 23
Figure 10: Mirapex, Parkinsons Disease, The UK, Sales Estimates ($m), 20022020 24
Figure 11: Mirapex, Parkinsons Disease, France, Sales Estimates ($m), 20022020 25
Figure 12: Mirapex, Parkinsons Disease, Germany, Sales Estimates ($m), 20022020 26
Figure 13: Mirapex, Parkinsons Disease, Italy, Sales Estimates ($m), 20022020 27
Figure 14: Mirapex, Parkinsons Disease, Spain, Sales Estimates ($m), 20022020 28
Figure 15: Mirapex, Parkinsons Disease, Japan, Sales Estimates ($m), 20032020 29
Figure 16: Mirapex, Parkinsons Disease, Global, Sales Distribution by Country (%), 2009 30
Figure 17: Drug Model Diagram 33
Figure 18: Patients Approved for the Drug 33

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *